Xponance Inc. Buys 5,346 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Xponance Inc. grew its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 8.4% during the 4th quarter, HoldingsChannel reports. The firm owned 68,810 shares of the company’s stock after acquiring an additional 5,346 shares during the quarter. Xponance Inc.’s holdings in GE HealthCare Technologies were worth $5,380,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of GEHC. Darwin Wealth Management LLC bought a new stake in shares of GE HealthCare Technologies in the 3rd quarter valued at approximately $31,000. Continuum Advisory LLC grew its stake in shares of GE HealthCare Technologies by 101.8% in the 3rd quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock valued at $31,000 after purchasing an additional 168 shares during the period. Bank of Jackson Hole Trust bought a new stake in shares of GE HealthCare Technologies in the 4th quarter valued at approximately $32,000. OFI Invest Asset Management bought a new stake in shares of GE HealthCare Technologies in the 4th quarter valued at approximately $34,000. Finally, Flagship Wealth Advisors LLC bought a new stake in shares of GE HealthCare Technologies in the 4th quarter valued at approximately $34,000. 82.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on GEHC shares. Wells Fargo & Company upped their price objective on GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. The Goldman Sachs Group upgraded GE HealthCare Technologies from a “neutral” rating to a “buy” rating and increased their price target for the stock from $85.00 to $100.00 in a research report on Tuesday, March 11th. Citigroup increased their price target on GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Finally, Jefferies Financial Group upgraded GE HealthCare Technologies from a “hold” rating to a “buy” rating and increased their price target for the stock from $95.00 to $103.00 in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, GE HealthCare Technologies has a consensus rating of “Moderate Buy” and a consensus target price of $98.75.

GE HealthCare Technologies Stock Up 0.3 %

NASDAQ:GEHC opened at $82.40 on Thursday. The stock’s fifty day moving average price is $87.17 and its two-hundred day moving average price is $86.08. The company has a market cap of $37.68 billion, a price-to-earnings ratio of 19.03, a P/E/G ratio of 3.19 and a beta of 1.13. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.83 and a current ratio of 1.04. GE HealthCare Technologies Inc. has a 52-week low of $74.51 and a 52-week high of $94.80.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.19. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. The company had revenue of $5.32 billion during the quarter, compared to analysts’ expectations of $5.33 billion. On average, analysts anticipate that GE HealthCare Technologies Inc. will post 4.68 EPS for the current year.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.